Survival of motor neuron 2 pre-mRNA splicing machinery (SMN2 pre-mRNA splicing machinery)

The **Survival of motor neuron 2 pre-mRNA splicing machinery** refers to the multi-component molecular complexes and regulatory RNA structures that control the alternative splicing of the SMN2 pre-mRNA, specifically the inclusion or exclusion of exon 7. In healthy individuals, the nearly identical SMN1 gene produces full-length SMN protein, but in patients with *spinal muscular atrophy* (SMA), SMN2 becomes the primary source due to deletion or mutation of SMN1. However, a single nucleotide difference in SMN2 exon 7 disrupts recognition by the spliceosome and leads to frequent exon 7 skipping, resulting in a truncated, unstable SMN protein. The splicing machinery involved includes canonical spliceosomal snRNPs (U1, U2), as well as regulatory RNA elements such as TSL1 and TSL2 stem-loop structures that influence exon accessibility[1][2][3][4][5]. Therapeutic targeting of this machinery, through either small molecules (e.g., risdiplam, branaplam, PK4C9, SMN-C series) or antisense oligonucleotides (e.g., nusinersen), seeks to enhance exon 7 inclusion by either stabilizing U1 snRNP interaction, disrupting inhibitory stem-loop structures, or blocking splicing silencers[2][3][4][6]. Aberrant regulation of this machinery leads to defective SMN protein production, underlying the genetic pathology of SMA. The SMN2 pre-mRNA splicing machinery serves as a validated and heavily studied therapeutic target for treating SMA, with multiple approved drugs directly modulating its function.

Other names

SMN2 spliceosomeSMN2 splicing complexSMN2 exon 7 splicing machinery

Modulation of splicing complex assembly at SMN2 exon 7 (promoting exon inclusion); Disruption or stabilization of RNA stem-loop (TSL1/TSL2) structures to alter exon accessibility; Enhanced recruitment or stabilization of spliceosomal proteins (e.g., U1 snRNP) at the exon 7 splice site; Antisense oligonucleotide-mediated blocking of splicing silencers or enhancers